|
gptkbp:instance_of
|
gptkb:biotechnology
|
|
gptkbp:acquisition
|
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:advocacy
|
engaged with patient advocacy groups
|
|
gptkbp:brand
|
attempted to rebrand company
|
|
gptkbp:business_model
|
biopharmaceuticals
|
|
gptkbp:ceo
|
gptkb:John_H._Johnson
|
|
gptkbp:clinical_trial
|
gptkb:immunotherapy
Phase III trial for Provenge
metastatic castrate-resistant prostate cancer
reported positive clinical trial results
|
|
gptkbp:collaborations
|
academic institutions
|
|
gptkbp:competitors
|
other cancer immunotherapy companies
|
|
gptkbp:conflict
|
experienced financial difficulties
faced significant business challenges
|
|
gptkbp:financials
|
gptkb:2014
|
|
gptkbp:focus
|
cancer immunotherapy
|
|
gptkbp:founded
|
gptkb:1992
|
|
gptkbp:founder
|
Mitchell H. Gold
|
|
gptkbp:funding
|
secured funding from investors
|
|
gptkbp:future_prospects
|
uncertain future outlook.
|
|
gptkbp:has_advisory_board
|
composed of experts
|
|
gptkbp:headcount
|
approximately 500 employees
|
|
gptkbp:headquarters
|
gptkb:Seattle,_Washington
|
|
gptkbp:healthcare
|
April 2010
collaborated with healthcare providers
expanded patient access programs
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dendreon
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:instruction_set
|
developing additional therapies
|
|
gptkbp:invention
|
multiple patents on technology
|
|
gptkbp:investment
|
various venture capital firms
|
|
gptkbp:investment_strategy
|
volatile stock performance
|
|
gptkbp:is_effective_against
|
improved survival rates
|
|
gptkbp:market
|
gptkb:United_States
|
|
gptkbp:market_withdrawal
|
withdrew from certain markets
|
|
gptkbp:marketing_strategy
|
direct-to-physician marketing
|
|
gptkbp:partnership
|
gptkb:Astellas_Pharma
|
|
gptkbp:partnerships
|
formed strategic partnerships
|
|
gptkbp:patient_population
|
men with prostate cancer
|
|
gptkbp:product_type
|
therapeutic vaccine
|
|
gptkbp:production_location
|
gptkb:New_Jersey
|
|
gptkbp:products
|
Provenge
|
|
gptkbp:provides_guidance_on
|
included in treatment guidelines
|
|
gptkbp:publications
|
published research findings
|
|
gptkbp:regulatory_compliance
|
faced several regulatory hurdles
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:research_focus
|
personalized medicine
|
|
gptkbp:revenue
|
$100 million (2011)
|
|
gptkbp:stock_symbol
|
DNDN
|
|
gptkbp:targets
|
gptkb:Oncology
|
|
gptkbp:technology
|
dendritic cell therapy
|
|
gptkbp:treatment
|
monitored for effectiveness
|
|
gptkbp:bfsParent
|
gptkb:Valeant_Pharmaceuticals
|
|
gptkbp:bfsLayer
|
6
|